Form 8-K · Current Report · Filed 2024-05-30
Roivant Reports Q4 and FY 2024 Results, Authorizes $1.5B Share Repurchase
Roivant Sciences Ltd. reported its financial results for Q4 and FY 2024, highlighting positive clinical data for brepocitinib and Dermavant's progress with VTAMA. The company also authorized a $1.5B share repurchase program. Roivant's financial position was strong with $6.6B in cash and cash equivalents as of March 31, 2024. The company authorized a $1.5 billion share repurchase program following the repurchase of Sumitomo's entire stake, reducing outstanding shares by 9%.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001140361-24-027986
- CIK
- 0001635088
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$10.73
Next session
-3.4%
Since filing
+222.8%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
Exhibits (1)
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.